Neurolief Secures Strategic Investment from BrainsWay Ahead of ProlivRx Launch for Major Depressive Disorder Treatment

Neurolief, a brain stimulation company, has received a strategic investment from BrainsWay for its Proliv™Rx system, designed to treat Major Depressive Disorder. The partnership aims to expand access to non-invasive mental health treatments. Proliv™Rx is a wearable at-home therapy that uses brain neuromodulation to deliver effective brain stimulation. The investment reflects a strategic alignment between the two companies and highlights the need for innovative depression treatments.

Neurolief, a pioneering brain stimulation company specializing in non-invasive neuromodulation therapies, has secured a strategic investment from BrainsWay Ltd. [1] [2]. This investment marks a significant milestone as Neurolief awaits FDA approval and prepares for the commercial launch of its Proliv™Rx system, designed for the treatment of Major Depressive Disorder (MDD). The partnership aims to expand access to innovative, clinically validated, and non-invasive mental health treatments.

Proliv™Rx is a wearable at-home therapy that uses brain neuromodulation to deliver effective brain stimulation. This technology has the potential to revolutionize the treatment of MDD by providing a non-invasive, accessible alternative to traditional therapies. The partnership with BrainsWay, a global leader in non-invasive neurostimulation treatments, reflects a strategic alignment between the two companies, both of which are dedicated to advancing mental health care.

The urgent need for innovation in depression treatment is underscored by the fact that a significant subset of patients fails to respond adequately to traditional treatments such as antidepressant medications. This lack of accessible therapies highlights a critical gap in mental health care, emphasizing the need for effective and innovative treatment strategies. Proliv™Rx is designed to bridge this gap by offering a revolutionary, non-invasive brain neuromodulation therapy that can be administered at a mental health clinic or a patient's home.

Dr. Mark S. George, Professor of Psychiatry and Neurology at the Medical University of South Carolina, highlighted the potential of Neurolief's technology to address the unmet needs of patients who cannot access office-based therapies like TMS due to factors such as childcare responsibilities, jobs, or distance from clinics. Similarly, Dr. Linda Carpenter, Professor of Psychiatry at Brown University and Neuromodulation Program Director at Butler Hospital, expressed excitement about the potential of Proliv™Rx to prevent the progression to more severe and chronic illness by offering a practical and effective alternative to traditional treatments.

Neurolief's technology is currently FDA-cleared and CE-marked for the treatment of migraine. If granted, the company will be the first to offer an FDA-approved MDD treatment that can be delivered outside of the clinic. This groundbreaking development positions Neurolief to become a key player in the mental health technology sector, with the potential to significantly impact the lives of millions of people affected by MDD.

References:
[1] https://finance.yahoo.com/news/neurolief-prepares-launch-proliv-rx-133200092.html
[2] https://www.prnewswire.com/news-releases/neurolief-prepares-for-launch-of-its-prolivrx-system-for-major-depressive-disorder-with-strategic-investment-from-brainsway-302535853.html